A Phase I/II study aiming to recruit 30 stage I–III NSCLC patients plans to use a MUC1 peptide vaccine adjuvanted with Poly-ICLC, which has shown safety and immunogenicity as a therapeutic vaccine for metastatic castrate resistant prostate cancer patients and a preventative vaccine for patients harboring advanced colonic adenomas (NCT01720836) [162,163]. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.